J. B. Chemicals & Pharmaceuticals Limited
NSE: JBCHEPHARM BSE: JBCHEPHARM
NSE
1,828.40
15.10 (0.83%)
Prev Close
1813.3
Open Price
1824
Volume
376,867
Today Low / High
1809.6 / 1844
52 WK Low / High
1385.75 / 1952
Range
1,737 - 1,920
BSE
1,826.65
13.25 (0.73%)
Prev Close
1813.4
Open Price
1815.15
Volume
8,263
Today Low / High
1810.05 / 1844.45
52 WK Low / High
1303 / 1950.3
Range
1,735 - 1,918
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1828.4 (target range: 1,737 - 1,920), reflecting a change of 15.1 (0.83274%). On the BSE, it is listed at 1826.65 (target range: 1,735 - 1,918), showing a change of 13.25 (0.73067%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
11 Nov
1,824.00
0.24%
10 Nov
1,713.90
5.80%
07 Nov
1,675.00
1.67%
06 Nov
1,698.90
-0.42%
04 Nov
1,723.10
-1.43%
03 Nov
1,690.90
1.27%
31 Oct
1,717.00
-2.02%
30 Oct
1,699.80
0.39%
29 Oct
1,686.00
0.65%
28 Oct
1,701.00
-0.88%
27 Oct
1,710.00
-0.51%
24 Oct
1,721.50
-1.12%
23 Oct
1,703.30
0.32%
21 Oct
1,682.10
0.52%
20 Oct
1,709.00
-1.04%
17 Oct
1,670.30
1.38%
16 Oct
1,667.50
0.23%
15 Oct
1,655.90
0.70%
14 Oct
1,668.00
-0.53%
J. B. Chemicals & Pharmaceuticals Limited Graph
J. B. Chemicals & Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for J. B. Chemicals & Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,828.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,826.65 | 1,844.92 | 1,660.42 - 2,029.41 |
| 1,863.18 | 1,490.55 - 2,235.82 | ||
| 1,881.45 | 1,317.01 - 2,445.88 | ||
| Bearish Scenario | 1,826.65 | 1,808.38 | 1,627.55 - 1,989.22 |
| 1,790.12 | 1,432.09 - 2,148.14 | ||
| 1,771.85 | 1,240.30 - 2,303.41 |
Overview of J. B. Chemicals & Pharmaceuticals Limited
ISIN
INE572A01036
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
155,640
Market Cap
286,320,563,388
Last Dividend
15.5
Official Website
IPO Date
2002-07-01
DCF Diff
-1,397.41
DCF
3,221
Financial Ratios Every Investor Needs
Stock Dividend of JBCHEPHARM
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-07-30 | July 30, 25 | 7 | 7 | 2025-07-30 | 2025-08-13 | |
| 2025-02-07 | February 07, 25 | 8.5 | 8.5 | 2025-02-08 | 2025-02-21 | |
| 2024-08-14 | August 14, 24 | 6.75 | 6.75 | 2024-08-14 | 2024-09-20 | |
| 2024-02-16 | February 16, 24 | 5.5 | 5.5 | 2024-02-16 | 2024-03-07 | |
| 2023-08-17 | August 17, 23 | 4.625 | 9.25 | 2023-08-17 | 2023-09-23 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 3,917.99 Cr | 1,316.55 Cr | 2,601.44 Cr | 0.6640 | 44.84 Cr | 36.25 Cr | 1,913.83 Cr | 659.58 Cr | 42.45 | 1,031.84 Cr | 0.1683 |
| 2024-03-31 | 3,484.18 Cr | 2,121.75 Cr | 1,345.88 Cr | 0.3863 | 30.56 Cr | 603.43 Cr | 754.16 Cr | 552.63 Cr | 35.66 | 933.48 Cr | 0.1586 |
| 2023-03-31 | 3,116.51 Cr | 2,015.49 Cr | 1,114.44 Cr | 0.3576 | 31.93 Cr | 547.04 Cr | 584.51 Cr | 409.84 Cr | 26.50 | 704.37 Cr | 0.1315 |
| 2022-03-31 | 2,424.24 Cr | 863.37 Cr | 1,560.87 Cr | 0.6439 | 29.11 Cr | 441.28 Cr | 460.48 Cr | 385.36 Cr | 24.93 | 581.53 Cr | 0.1590 |
| 2021-03-31 | 2,005.85 Cr | 717.44 Cr | 1,288.41 Cr | 0.6423 | 23.53 Cr | 341.95 Cr | 455.67 Cr | 447.96 Cr | 28.98 | 672.26 Cr | 0.2233 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 129.45 Cr | 4,273.78 Cr | 840.46 Cr | 3,433.3200 Cr | 27.89 Cr | -101.56 Cr | 528.95 Cr | 656.64 Cr | 10.32 Cr | 1.90 Cr | 27.98 Cr | 632.3300 Cr |
| 2024-03-31 | 88.22 Cr | 3,994.13 Cr | 1,070.80 Cr | 2,923.3300 Cr | 377.66 Cr | 289.44 Cr | 502.51 Cr | 634.88 Cr | 12.99 Cr | 1.70 Cr | 29.09 Cr | 868.2261 Cr |
| 2023-03-31 | 76.93 Cr | 3,553.87 Cr | 1,073.52 Cr | 2,480.3500 Cr | 572.45 Cr | 495.52 Cr | 430.49 Cr | 576.42 Cr | 118.25 Cr | 2.49 Cr | 28.09 Cr | 554.4500 Cr |
| 2022-03-31 | 56.54 Cr | 2,607.40 Cr | 468.79 Cr | 2,134.1230 Cr | 54.56 Cr | -1.99 Cr | 409.96 Cr | 566.82 Cr | 116.47 Cr | 3.17 Cr | 12.72 Cr | 383.7156 Cr |
| 2021-03-31 | 28.69 Cr | 2,238.12 Cr | 424.69 Cr | 1,809.7248 Cr | 44.99 Cr | 16.30 Cr | 347.45 Cr | 569.66 Cr | 108.56 Cr | 4.93 Cr | -651.88 Cr | 345.2737 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 902.4500 Cr | -295.8900 Cr | -579.6800 Cr | 804.8600 Cr | 26.8700 Cr | 115.0900 Cr | -97.5900 Cr | 659.5800 Cr | -343.9200 Cr | -237.0400 Cr | -26.4400 Cr |
| 2024-03-31 | 800.6117 Cr | -407.9074 Cr | -341.2720 Cr | 539.2447 Cr | 11.0507 Cr | 88.2151 Cr | -126.1128 Cr | 552.6278 Cr | -191.5957 Cr | -156.9875 Cr | -72.0300 Cr |
| 2023-03-31 | 625.6100 Cr | -961.7900 Cr | 356.5400 Cr | -139.3400 Cr | 20.3900 Cr | 76.9300 Cr | -764.9500 Cr | 555.2300 Cr | 523.1596 Cr | -127.5926 Cr | -20.5200 Cr |
| 2022-03-31 | 170.1345 Cr | 2.3199 Cr | -138.3851 Cr | -536.6547 Cr | 34.0703 Cr | 56.5441 Cr | -706.7892 Cr | 504.9020 Cr | -0.3273 Cr | -127.5628 Cr | -62.5143 Cr |
| 2021-03-31 | 314.7849 Cr | -230.6758 Cr | -87.4228 Cr | 267.0119 Cr | -3.2782 Cr | 22.4737 Cr | -47.7730 Cr | 596.8854 Cr | 0.3223 Cr | -73.2403 Cr | -70.0857 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,093.94 Cr | 584.09 Cr | 509.85 Cr | 0.4661 | 258.17 Cr | 202.38 Cr | 12.97 | 315.42 Cr | 0.1850 |
| 2025-03-31 | 949.48 Cr | 321.64 Cr | 627.84 Cr | 0.6612 | 1,233.03 Cr | 145.69 Cr | 9.36 | 222.76 Cr | 0.1534 |
| 2024-12-31 | 963.49 Cr | 316.74 Cr | 646.75 Cr | 0.6713 | 212.57 Cr | 162.49 Cr | 10.46 | 262.51 Cr | 0.1686 |
| 2024-09-30 | 1,000.62 Cr | 550.87 Cr | 449.75 Cr | 0.4495 | 228.64 Cr | 174.57 Cr | 11.24 | 280.47 Cr | 0.1745 |
| 2024-06-30 | 1,004.40 Cr | 547.44 Cr | 456.96 Cr | 0.4550 | 239.59 Cr | 176.83 Cr | 11.39 | 286.26 Cr | 0.1761 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 450.09 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,433.32 Cr |
| 2025-03-31 | 129.45 Cr | 335.00 Cr | 446.56 Cr | 815.38 Cr | 528.95 Cr | 1,922.74 Cr | 656.64 Cr | 4,273.78 Cr | 840.46 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 416.86 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -3,212.23 Cr |
| 2024-09-30 | 97.46 Cr | 319.40 Cr | 416.86 Cr | 817.14 Cr | 543.67 Cr | 1,913.30 Cr | 641.67 Cr | 4,029.41 Cr | 817.18 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 459.64 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,923.33 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 202.38 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 145.69 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 162.49 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 174.57 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 176.83 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2023-09-18 | September 18, 23 | 2:1 |
| 2005-04-05 | April 05, 05 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,716.10 | ₹4,117,498,742,017.00 | ₹1,315,335.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,539.50 | ₹1,736,034,525,500.00 | ₹388,944.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,825.80 | ₹1,294,822,881,000.00 | ₹623,704.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,211.50 | ₹1,008,409,076,863.00 | ₹1,048,484.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹938.90 | ₹944,749,347,000.00 | ₹1,819,764.00 |
| Mankind Pharma Limited | MANKIND | ₹2,220.50 | ₹916,530,227,045.00 | ₹428,573.00 |
| Lupin Limited | LUPIN | ₹1,975.90 | ₹902,516,391,462.00 | ₹1,666,170.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,696.50 | ₹681,102,022,500.00 | ₹124,473.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,168.20 | ₹678,492,455,989.00 | ₹1,481,103.00 |
| Laurus Labs Limited | LAURUSLABS | ₹985.70 | ₹532,105,402,944.00 | ₹1,827,992.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,817.30 | ₹512,843,530,196.00 | ₹388,860.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,322.00 | ₹335,396,976,196.00 | ₹48,373.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,577.60 | ₹322,034,064,422.00 | ₹78,777.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,828.40 | ₹286,320,563,388.00 | ₹376,867.00 |
| Cohance Lifesciences Limited | COHANCE | ₹691.05 | ₹264,373,022,097.00 | ₹234,960.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,369.70 | ₹259,646,970,936.00 | ₹434,122.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,150.00 | ₹228,750,000,000.00 | ₹12,335.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹17,193.00 | ₹220,584,281,577.00 | ₹75,550.00 |
| Eris Lifesciences Limited | ERIS | ₹1,596.70 | ₹217,492,181,672.00 | ₹70,338.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,331.80 | ₹216,398,854,800.00 | ₹258,472.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹916.95 | ₹180,238,556,552.00 | ₹38,416.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,117.70 | ₹177,153,700,800.00 | ₹124,861.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,947.90 | ₹148,063,182,638.00 | ₹47,804.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹792.95 | ₹142,025,171,417.00 | ₹314,876.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹535.45 | ₹129,936,963,982.00 | ₹831,053.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹913.60 | ₹112,081,679,533.00 | ₹36,382.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,947.00 | ₹98,716,524,754.00 | ₹4,906.00 |
| Strides Pharma Science Limited | STAR | ₹925.30 | ₹85,287,412,264.00 | ₹800,331.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹393.40 | ₹76,941,886,414.00 | ₹400,966.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹771.55 | ₹69,938,915,828.00 | ₹243,122.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹438.60 | ₹67,150,562,639.00 | ₹140,961.00 |
| FDC Limited | FDC | ₹409.00 | ₹66,589,324,356.00 | ₹146,352.00 |
| Sequent Scientific Limited | SEQUENT | ₹228.72 | ₹57,160,066,823.00 | ₹2,472,684.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹449.65 | ₹48,996,231,407.00 | ₹115,102.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹474.95 | ₹43,348,686,500.00 | ₹1,088,592.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹131.09 | ₹42,541,534,971.00 | ₹291,334.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹821.35 | ₹41,658,136,892.00 | ₹98,481.00 |
| Innova Captab Limited | INNOVACAP | ₹709.85 | ₹40,621,115,851.00 | ₹60,025.00 |
| Suven Life Sciences Limited | SUVEN | ₹182.42 | ₹39,774,983,947.00 | ₹161,298.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,366.10 | ₹39,132,963,392.00 | ₹5,662.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹481.90 | ₹33,928,530,925.00 | ₹276,531.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹318.60 | ₹31,950,006,412.00 | ₹38,447.00 |
Key Executives
Executive Vice President of Operations of Daman
Mr. Parmeshwar B. Bang
Gender: male
Year Born: 1968
Vice President of Legal
Mr. Himanshu Ranvah
Gender: male
Year Born: 1985
Vice President of Finance & Accounts
Mr. Bhagwat Singh Deora
Gender: male
Year Born: 1982
Vice President of Information & Technology
Mr. Suresh Bhise
Gender: male
Year Born: 1966
Vice President of HR & Administration
Mr. Sridhar Bharadwaj
Gender: male
Year Born: 1967
Chief Financial Officer
Mr. Narayan Saraf
Gender: male
Year Born: 1980
Assistant Vice President Human Resource
Suresh Amin
Gender: Not Specified
Year Born:
President of Operations
Mr. Kunal Khanna
Gender: male
Year Born: 1980
President of Global Business
Mr. Pradeep Kumar Singh
Gender: male
Year Born: 1964
Chief Executive Officer & Whole-Time Director
Mr. Nikhil Ashokkumar Chopra
Gender: male
Year Born: 1973
FAQs about J. B. Chemicals & Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Nikhil Ashokkumar Chopra.
What is the current market price of the stock?
The current price is ₹1,828.40.
What is the 52-week price range?
The range is ₹1385.75-1952.
What is the market capitalization of the company?
The market capitalization is ₹28,632.06 crores.
What is the dividend yield?
The dividend yield is 0.85%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 41.65.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of J. B. Chemicals & Pharmaceuticals Limited (ISIN: INE572A01036) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹28,632.06 crores and an average daily volume of 155,640 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹15.5.